Redefining Dermatology Through Peptide-Drug Conjugates
Unlocking safer, more effective, consumer-friendly treatments for hair loss and inflammatory skin therapies.
Existing treatments for conditions like hair loss and inflammatory skin disorders face significant challenges:
Limited Efficacy
Many active ingredients do not penetrate deeply enough into the skin or scalp to achieve their full therapeutic effect.
Formulation Barriers
Common solutions rely on ethanol-based systems that can cause irritation, instability, or compliance issues.
Safety Concerns
Some treatments risk systemic exposure or side effects, limiting long-term use and consumer acceptance.
Our Solution
Absotride™ conjugates improve delivery, penetration, and bioavailability of dermatology actives while maintaining an excellent safety profile.
Key Advantages
- Clinically relevant efficacy – Absotride conjugates show 35–42% inhibition vs. 28–65% with finasteride.
- Formulation flexibility – zero-ethanol, high-solubility systems compatible with topical formats.
- Safety-first design – no irritation observed and no blood exposure over 24 hours.
Potential Applications
- Hair Loss Therapy – safer, more effective alternatives to conventional finasteride-based products.
- Inflammatory Skin Disorders – improved delivery of actives for localized treatment.
- Novel Topical Combinations – enabling next-generation peptide-drug formulations.
Actives Enabled by Absotride
- Hair Regrowth & Scalp Health: Finasteride, Minoxidil, and emerging topical actives
- Repair & Regeneration: enhanced efficacy of growth factors, peptides, and novel biologics to support skin healing and renewal
With Absotride, brands and researchers can deliver safer, more effective treatments in consumer-friendly topical formats—without relying on harsh enhancers or irritating solvents.